Boar's Head deadly listeria outbreak: Food safety lawyer asks Congress to investigate
A food safety lawyer is asking Congress to take action and investigate Boar's Head due to the company's ties to the largest listeria outbreak since 2011.
You can raise life expectancy by ‘three years’ with walking 20 minutes a day: Dan Buettner
Blue Zones founder Dan Buettner breaks down the best ways to increase your life’s longevity using exercise and diet on ‘Mornings with Maria.’
Schools facing another growing problem: chronic absenteeism
Chronic absenteeism isn't a new problem. It's something that's been going on even before the pandemic. As the new school year begins, educators are honing in on this problem.
Grocery chain joins Walmart, CVS, others in ending cigarettes sales
Stop & Shop is the latest company to remove cigarettes and other tobacco products from its shelves. The company says it is part of its commitment to wellness.
Eli Lilly cuts cost of certain Zepbound doses by at least 50%
Eli Lilly is launching more supply of its weight loss drug Zepbound. The new single-dose vials will be priced lower than "all other incretin GLP-1 medicines for obesity."
Walgreens, Bilt launch automatic FSA/HSA savings program
Bilt CEO Ankur Jain explains how members will be able to use their FSA/HSA accounts toward their Walgreens purchases.
Your next Walgreens trip may not cost you as much. Here's why.
Bilt, a rewards program, teamed up with Walgreens to help members use the hundreds of dollars they have available in their FSA/HSA accounts that typically go unused.
Employer health care costs expected to jump 9% in US next year
Inflation might be easing in some areas of the economy, but employers can expect to spend 9% more on health care costs next year, driven by an increasing claims and prescription drug costs.
Gov. J.B. Pritzker: Trump is rich in only one thing — stupidity
Democratic Illinois Gov. J.B. Pritzker targets former President Trump and Republican policies in his Democratic National Convention speech.
Eli Lilly's Zepbound reduces type 2 diabetes risk, study shows
Eli Lilly announced results of a study in which weekly shots of tirzepatide injections significantly reduced the risk of progression to type 2 diabetes by 94% among certain adults.
Medtronic CEO: We're allocating more capital towards diabetes tech
Medtronic Chairman and CEO Geoffrey Martha discusses Johnson & Johnson acquiring V-Wave on 'The Claman Countdown.'
Harris' economic plan would add over $1.7T to national debt: CRFB
Vice President Harris released part of her economic agenda aimed at lowering costs for families, which the nonpartisan CRFB estimates would add $1.7 trillion to the national debt.
Everybody that owns property around the country will benefit from a Trump win: Grant Cardone
Cardone Capital CEO Grant Cardone weighs in on the real estate market, the impact of a possible Trump or Harris presidency, and his 10X Wealth Conference.
California reignites war on gas stoves with newly proposed law
California legislators are trying to pass a bill that would require warning labels be placed on gas stoves, alerting customers about potential health risks associated with the products.
Over 100 illnesses tied to mushroom-infused 'microdosing' chocolate bars
More than 100 illnesses, including over 40 hospitalizations, have been linked to the Diamond Shruumz-branded chocolate bars, cones or gummies that were recalled in June.
Boar's Head listeria outbreak: Another death, 10 more hospitalized, CDC says
The deaths and illnesses related to the multi-state outbreak of listeria continues to grow. Officials have tied to the outbreak to deli meats, including from Boar's Head.
Biden rewriting Inflation Reduction Act to avoid drug price crisis ahead of election: 'The Bottom Line'
Former White House Council of Economic Advisers acting chairman Tomas Philipson explains the political fallout of the Inflation Reduction Act on 'The Bottom Line.'
Eli Lilly raises forecast after boost in Zepbound, Mounjaro sales
Eli Lilly and Co. reported strong second-quarter results, beating Wall Street estimates and prompting the company to raise its full-year revenue forecast by $3 billion.
Novo Nordisk slashes outlook even as it ramps up Wegovy production
Danish drug maker Novo Nordisk lowered its full year forecast even as tens of thousands of patients start the highly coveted weight loss drug, Wegovy, every week.
CVS cuts outlook, plans $2B cost-cutting effort
CVS said Wednesday that it's launching a multi-year productivity initiative. It also cut its outlook for the year as its health care benefits segment continues to face pressure.